6FN logo

Klaria Pharma Holding AB (publ.) DB:6FN Stock Report

Last Price

€0.026

Market Cap

€4.0m

7D

-26.6%

1Y

31.3%

Updated

16 Jun, 2024

Data

Company Financials +

Klaria Pharma Holding AB (publ.)

DB:6FN Stock Report

Market Cap: €4.0m

Klaria Pharma Holding AB (publ.) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Klaria Pharma Holding AB (publ.)
Historical stock prices
Current Share Pricekr0.026
52 Week Highkr0.075
52 Week Lowkr0.01
Beta0.32
1 Month Change-12.16%
3 Month Change12.07%
1 Year Change31.31%
3 Year Change-96.96%
5 Year Changen/a
Change since IPO-96.14%

Recent News & Updates

Recent updates

Shareholder Returns

6FNDE PharmaceuticalsDE Market
7D-26.6%-0.7%-3.1%
1Y31.3%-18.1%-0.5%

Return vs Industry: 6FN exceeded the German Pharmaceuticals industry which returned -18.1% over the past year.

Return vs Market: 6FN exceeded the German Market which returned -0.5% over the past year.

Price Volatility

Is 6FN's price volatile compared to industry and market?
6FN volatility
6FN Average Weekly Movement45.6%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement5.0%
10% most volatile stocks in DE Market10.3%
10% least volatile stocks in DE Market2.5%

Stable Share Price: 6FN's share price has been volatile over the past 3 months.

Volatility Over Time: 6FN's weekly volatility has increased from 39% to 46% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20145Scott Boyerwww.klaria.com

Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company. It develops Sumatriptan for the treatment of migraine. The company also develops Epinephrine/Adrenaline, which is in Phase I clinical trial for the treatment of acute allergic reaction.

Klaria Pharma Holding AB (publ.) Fundamentals Summary

How do Klaria Pharma Holding AB (publ.)'s earnings and revenue compare to its market cap?
6FN fundamental statistics
Market cap€4.04m
Earnings (TTM)-€3.76m
Revenue (TTM)n/a

-7.0x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6FN income statement (TTM)
Revenue-kr6.53m
Cost of Revenuekr0
Gross Profit-kr6.53m
Other Expenseskr35.74m
Earnings-kr42.27m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 22, 2024

Earnings per share (EPS)-0.33
Gross Margin100.00%
Net Profit Margin647.55%
Debt/Equity Ratio0%

How did 6FN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.